What was studied?
Mice lacking the GHRH gene were followed after exposure to an albumin-binding, long-acting CJC-1295 analogue. Investigators measured growth, body composition, bone lengths and pituitary-related measurements across experimental intervals.
What did the researchers report?
The reported growth and body-composition responses varied with exposure interval, with more complete normalization in one investigated condition. Pituitary RNA and tissue findings were consistent with changes in growth-hormone-producing cells.
What are the limits?
A gene-knockout model tests a defined deficiency and does not demonstrate growth or performance enhancement in healthy humans. The albumin-binding analogue is not interchangeable with no-DAC products. Animal timing experiments should not be converted into personal-use schedules or evidence of catalog-material safety.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.